###begin article-title 0
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
A Genome-Wide Association Study Reveals Variants in ARL15 that Influence Adiponectin Levels
###end article-title 0
###begin p 1
Ran meta-analysis: J. B. Richards, K. Song. Ran statistical analysis in studies: J. B. Richards, D. Waterworth, M.-F. Hivert, R. J. F. Loos, J. R. B. Perry, T. Tanaka, N. J. Timpson, K. Song, C. Langenberg, I. Prokopenko, R. Saxena, Y. Aluchenko, D. Evans, J. Erdmann, C. Willenborg, J. C. M. Witteman, B. Glaser, I. R. Konig, C. M. Van Duijn, T. M. Frayling. Designed studies: J. B. Richards, D. Waterworth, J. Dupuis, J. C. Florez, G. Waeber, J. Erdmann, M.-S. Burnett, J. Devaney, P. Vollenweider, C. Hengstenberg, L. Ferruci, D. Melzer, K. Stark, J. Deanfield, A. S. Hall, J. M. Egan, S. Grundy, P. Barter, Y. A. Kesaniemi, D. J. Rader, M. P. Reilly, S. E. Epstein, A. F. R. Stewart, N. J. Samani, R. McPherson, N. J. Wareham, J. B. Weigs, V. Mooser, T. D. Spector. Established the consortium: J. B. Richards, D. Waterworth, C. Hengstenberg, V. Mooser, T. D. Spector. Interpreted results and critically read the manuscript: J. B. Richards, D. Waterworth, S. O'Rahilly, M.-F. Hivert, R. J. F. Loos, J. R. B. Perry, T. Tanaka, N. J. Timpson, R. K. Semple, N. Soranzo, K. Song, N. Rocha, E. Grundberg, J. Dupuis, J. C. Florez, C. Langenberg, I. Prokopenko, R. Saxena, R. Sladek, Y. Aluchenko, D. Evans, G. Waeber, J. Erdmann, M.-S. Burnett, N. Sattar, J. Devaney, C. Willenborg, A. Hingorani, J. C. M. Witteman, P. Vollenweider, B. Glaser, C. Hengstenberg, L. Ferruci, D. Melzer, K. Stark, J. Deanfield, J. Winogradow, M. Grassl, A. S. Hall, J. M. Egan, J. R. Thompson, S. L. Ricketts, I. R. Konig, W. Reinhard, S. Grundy, H. E. Wichmann, P. Barter, R. Mahley, Y. A. Kesaniemi, D. J. Rader, M. P. Reilly, S. E. Epstein, A. F. R. Stewart, C. M. Van Duijn, H. Schunkert, K. Burling, P. Deloukas, T. Pastinen, N. J. Samani, R. McPherson, G. Davey Smith, T. M. Frayling, N. J. Wareham, J. B. Weigs, V. Mooser, T. D. Spector. Wrote the first draft of the manuscript: J. B. Richards. Coordinated/collected phenotypic information: D. W, G. Waeber, M.-S. Burnett, N. Sattar, J. Devaney, A. Hingorani, P. Vollenweider, C. Hengstenberg, K. Stark, J. Winogradow, M. Grassl, A. S. Hall, S. L. Ricketts, W. Reinhard, S. Grundy, H. E. Wichmann, P. Barter, R. Mahley, Y. A. Kesaniemi, D. J. Rader, M. P. Reilly, S. E. Epstein, N. J. Samani, R. McPherson, G. Davey Smith, J. B. Weigs, V. Mooser, T. D. Spector. Performed expression studies: S. O'Rahilly, R. K. Semple, N. Rocha, E. Grundberg, T. Pastinen. Coordinated GWA genotyping of studies: N. Soranzo, J. Erdmann, C. Hengstenberg, K. Stark, M. P. Reilly, H. Schunkert, P. Deloukas, T. D. Spector. Obtained funding: J. Dupuis, J. C. Florez, J. Erdmann, N. Sattar, C. Hengstenberg, A. S. Hall, J. M. Egan, J. R. Thompson, D. J. Rader, M. P. Reilly, S. E. Epstein, A. F. R. Stewart, N. J. Samani, R. McPherson, G. Davey Smith, N. J. Wareham, J. B. Weigs, T. D. Spector. Performed laboratory analyses: N. Sattar, K. Stark, J. M. Egan, K. Burling, R. McPherson. Provided data for the BMI trait: GIANT Consortium.
###end p 1
###begin p 2
###xml 460 462 458 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 695 701 691 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
###xml 792 795 788 791 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;19</sup>
###xml 856 861 852 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 994 996 990 992 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 1036 1041 1032 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 1123 1125 1119 1121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 1202 1204 1198 1200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;3</sup>
###xml 1271 1277 <span type="species:ncbi:9606">humans</span>
The adipocyte-derived protein adiponectin is highly heritable and inversely associated with risk of type 2 diabetes mellitus (T2D) and coronary heart disease (CHD). We meta-analyzed 3 genome-wide association studies for circulating adiponectin levels (n = 8,531) and sought validation of the lead single nucleotide polymorphisms (SNPs) in 5 additional cohorts (n = 6,202). Five SNPs were genome-wide significant in their relationship with adiponectin (P</=5x10-8). We then tested whether these 5 SNPs were associated with risk of T2D and CHD using a Bonferroni-corrected threshold of P</=0.011 to declare statistical significance for these disease associations. SNPs at the adiponectin-encoding ADIPOQ locus demonstrated the strongest associations with adiponectin levels (P-combined = 9.2x10-19 for lead SNP, rs266717, n = 14,733). A novel variant in the ARL15 (ADP-ribosylation factor-like 15) gene was associated with lower circulating levels of adiponectin (rs4311394-G, P-combined = 2.9x10-8, n = 14,733). This same risk allele at ARL15 was also associated with a higher risk of CHD (odds ratio [OR] = 1.12, P = 8.5x10-6, n = 22,421) more nominally, an increased risk of T2D (OR = 1.11, P = 3.2x10-3, n = 10,128), and several metabolic traits. Expression studies in humans indicated that ARL15 is well-expressed in skeletal muscle. These findings identify a novel protein, ARL15, which influences circulating adiponectin levels and may impact upon CHD risk.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 582 588 582 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
###xml 665 670 665 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 908 913 908 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 978 983 978 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
Through a meta-analysis of genome-wide association studies of 14,733 individuals, we identified common base-pair variants in the genome which influence circulating adiponectin levels. Since adiponectin is an adipocyte-derived circulating protein which has been inversely associated with risk of obesity-related diseases such as type 2 diabetes (T2D) and coronary heart disease (CHD), we next sought to understand if the identified variants influencing adiponectin levels also influence risk of T2D, CHD, and several metabolic traits. In addition to confirming that variation at the ADIPOQ locus influences adiponectin levels, our analyses point to a variant in the ARL15 (ADP-ribosylation factor-like 15) locus which decreases adiponectin levels and increases risk of CHD and T2D. Further, this same variant was associated with increased fasting insulin levels and glycated hemoglobin. While the function of ARL15 is not known, we provide insight into the tissue specificity of ARL15 expression. These results thus provide novel insights into the physiology of the adiponectin pathway and obesity-related diseases.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 80 83 80 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Hivert1">[1]</xref>
###xml 84 87 84 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Hung1">[2]</xref>
###xml 88 91 88 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Wannamethee1">[3]</xref>
###xml 115 118 115 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Lindsay1">[4]</xref>
###xml 119 122 119 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Weyer1">[5]</xref>
###xml 123 126 123 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Spranger1">[6]</xref>
###xml 156 159 156 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Pischon1">[7]</xref>
###xml 301 308 301 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 352 355 352 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Hoffstedt1">[8]</xref>
###xml 356 359 356 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Peake1">[9]</xref>
Adiponectin is an adipocyte-secreted protein that increases insulin sensitivity [1],[2],[3], and has anti-diabetic [4],[5],[6] and anti-atherogenic effects [7]. Several features render adiponectin an attractive and tractable biomarker for large epidemiologic studies, such as its long half-life, high ex vivo stability, and minimal diurnal variability [8],[9].
###end p 6
###begin p 7
###xml 55 59 55 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Comuzzie1">[10]</xref>
###xml 60 64 60 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Vasseur1">[11]</xref>
###xml 65 69 65 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Menzaghi1">[12]</xref>
###xml 187 193 187 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
###xml 329 333 329 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Menzaghi1">[12]</xref>
###xml 334 338 334 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Hivert2">[13]</xref>
###xml 339 343 339 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Ling1">[14]</xref>
###xml 484 488 484 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Menzaghi1">[12]</xref>
While adiponectin levels are highly heritable (30-70%) [10],[11],[12], several well-designed studies have shown variable association between common polymorphisms in the adiponectin gene (ADIPOQ), possibly due to small sample sizes and different panels of single nucleotide polymorphisms (SNPs), ethnicities and clinical outcomes [12],[13],[14]. This has lead some observers to call for a more complete and systematic characterization of the genetic determinants of adiponectin levels [12].
###end p 7
###begin p 8
###xml 129 135 129 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
Our study therefore sought to address 2 questions: first, what are the common genetic determinants of adiponectin levels both at ADIPOQ and elsewhere? And second, do the variants robustly associated with adiponectin levels influence metabolic traits and risk of metabolic disease?
###end p 8
###begin p 9
###xml 370 372 370 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
###xml 719 723 719 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Zeggini1">[15]</xref>
###xml 846 850 846 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Prokopenko1">[16]</xref>
###xml 1089 1096 1089 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000768.s008">Text S1</xref>
###xml 1098 1102 1098 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Willer1">[17]</xref>
###xml 1103 1107 1103 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Loos1">[18]</xref>
###xml 1122 1130 1122 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000768-g001">Figure 1</xref>
###xml 264 276 <span type="species:ncbi:9606">participants</span>
To comprehensively assess the influence of common genetic variation on circulating adiponectin levels, we undertook a large-scale meta-analysis of 3 genome-wide association studies (GWAS) for circulating adiponectin levels from population-based cohorts (n = 8,531 participants). From this first stage, we chose SNPs most strongly associated with adiponectin levels (P<10-4, n = 250), and tested these for their association with adiponectin in 5 additional population-based cohorts (n = 6,202). The 5 SNPs which achieved genome-wide significance in the combined stage were then tested for their association with: type 2 diabetes mellitus (T2D) in the Diabetes Genetics Replication And Meta-analysis (DIAGRAM) consortium [15] (n = 10,128); indices of insulin resistance in the Meta-Analysis of Glucose and Insulin-related traits Consortium (MAGIC) [16] (n = 24,188); risk of coronary heart disease (CHD) in a consortium of 8 cohorts with available genome-wide association data (n = 22,421); and body mass index (BMI) in the Genetic Investigation of Anthropometric Traits (GIANT) consortium (Text S1) [17],[18] (n = 32,527) (Figure 1).
###end p 9
###begin title 10
Overall study design.
###end title 10
###begin title 11
Results
###end title 11
###begin title 12
Genome-Wide Association Study for Circulating Adiponectin Levels
###end title 12
###begin p 13
###xml 191 198 191 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000768-t001">Table 1</xref>
###xml 284 286 282 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 348 355 346 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000768-t002">Table 2</xref>
###xml 454 460 452 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
###xml 497 500 495 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;19</sup>
###xml 503 510 501 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000768-t002">Table 2</xref>
###xml 512 521 510 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000768.s001">Figure S1</xref>
###xml 523 532 521 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000768.s002">Figure S2</xref>
###xml 559 565 557 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
###xml 812 819 810 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000768-t002">Table 2</xref>
To identify genetic variants influencing adiponectin levels, we performed a GWAS utilizing information from population-based cohorts including, in total, 14,733 subjects of European descent (Table 1). We identified 5 variants at 2 loci that achieved genome-wide significance (P</=5x10-8) for their relationship with circulating adiponectin levels (Table 2). The SNP most strongly associated with circulating adiponectin levels lies 30 kb upstream of the ADIPOQ locus (rs266717; P-combined = 9.2x10-19) (Table 2, Figure S1, Figure S2). In total, 4 SNPs at the ADIPOQ locus demonstrated genome-wide significant associations with circulating adiponectin. All 8 studies contributed to these genome-wide significant associations, with the exception of rs6444175, which demonstrated some heterogeneity across cohorts (Table 2).
###end p 13
###begin title 14
###xml 0 11 <span type="species:ncbi:9606">Participant</span>
Participant characteristics (n total for all cohorts = 14,733).
###end title 14
###begin p 15
Plasma.
###end p 15
###begin p 16
Serum.
###end p 16
###begin p 17
###xml 230 238 <span type="species:ncbi:9606">Children</span>
SD: Standard Deviation, GEMS: Genetic Etiology of Metabolic Syndrome, BLSA: Baltimore Longitudinal Study of Aging, EPIC-Norfolk: European Prospective Investigation of Cancer-Norfolk, ALSPAC: Avon Longitudinal Study of Parents and Children, ELISA: Enzyme-Linked Immunosorbent Assay, RIA: Radio-Immunoassay, BMI: Body Mass Index.
###end p 17
###begin title 18
###xml 136 143 136 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000768-t001">Table 1</xref>
Relationship of SNPs achieving genome-wide significance for their association with adiponectin levels (n = 14,733 from the 8 studies in Table 1).
###end title 18
###begin p 19
A1 = Effect Allele.
###end p 19
###begin p 20
Minor Allele. Effect Size is the change in Natural Log-Transformed adiponectin levels per effect allele.
###end p 20
###begin p 21
Chr: Chromosome, SNP: Single Nucleotide Polymorphism, MAF: Minor Allele Frequency, CI: Confidence Interval.
###end p 21
###begin p 22
###xml 76 81 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 205 207 205 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 210 217 210 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000768-t002">Table 2</xref>
###xml 219 227 219 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000768.s006">Table S3</xref>
###xml 229 237 229 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000768-g002">Figure 2</xref>
###xml 411 415 411 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Gillingham1">[19]</xref>
Our results also identified a novel intronic SNP (rs4311394) located in the ARL15 (ADP-ribosylation factor-like 15) gene whose G allele was robustly associated with decreased adiponectin levels (P = 2.9x10-8) (Table 2, Table S3, Figure 2). ARL15 is an ADP-ribosylation factor-like GTP-binding protein, whose function is unknown, yet belongs to a family of proteins involved in intracellular vesicle trafficking [19].
###end p 22
###begin title 23
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
Association between SNPs near ARL15 and adiponectin levels.
###end title 23
###begin p 24
###xml 680 688 <span type="species:ncbi:9606">Children</span>
(A) -Log(P-value) measures for association between single nucleotide polymorphisms (SNPs) and chromosomal position. (B) Linkage disequilibrium in GOLD heat map Haploview 4.0 color scheme, CEPH (Centre d'Etude du Polymorphisme Humain) population. The x axis represents genomic position in Mb (A) and in kb (B). All P-values are derived from the discovery meta-analysis of CoLaus, TwinsUK, and Genetic Etiology of Metabolic Syndrome (GEMS) cohorts, except that for the lead SNP, rs4311394 (in red), which is derived from the combined P-value from the CoLaus, TwinsUK, GEMS, Framingham, InCHIANTI, Baltimore Longitudinal Study of Aging (BLSA), Avon Longitudinal Study of Parents and Children (ALSPAC), and European Prospective Investigation of Cancer-Norfolk (EPIC-Norfolk) cohorts.
###end p 24
###begin title 25
Association with Metabolic Disease and Metabolic Traits
###end title 25
###begin p 26
###xml 335 342 335 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Methods</xref>
###xml 617 623 613 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
###xml 804 811 800 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000768-t003">Table 3</xref>
###xml 813 820 809 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000768-t004">Table 4</xref>
###xml 822 830 818 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000768.s007">Table S4</xref>
###xml 855 861 851 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
Since glycemia, T2D and CHD have been correlated with adiponectin levels, we tested whether genome-wide significant SNPs for adiponectin levels were associated with glycemia, indices of insulin resistance, and risk of T2D and CHD. Since 5 SNPs (which, due to linkage disequilibrium, represented 4.59 independent statistical tests [see Methods]) were tested for their association with T2D, CHD and metabolic traits, we employed a conservative Bonferroni-corrected threshold of alpha = 0.011 (where 0.011 = 0.05/4.59) to declare statistical significance for these metabolic diseases and traits. None of the SNPs at the ADIPOQ locus demonstrated a robust relationship with T2D, CHD, homeostasis model assessment insulin resistance (HOMA-IR), homeostasis model assessment beta-cell function (HOMA-B) or BMI (Table 3, Table 4, Table S4). However rs1648707, at ADIPOQ, was associated with a non-statistically significant trend for its relationship with CHD (P = 0.04) and T2D (P = 0.046).
###end p 26
###begin title 27
Association of genome-wide significant SNPs with risk of type 2 diabetes mellitus (T2D) and coronary heart disease (CHD) (n = 10,128 for T2D; n = 22,421 for CHD).
###end title 27
###begin p 28
SNP: Single Nucleotide Polymorphism, CI: Confidence Interval.
###end p 28
###begin title 29
Association of genome-wide significant SNPs with indices of insulin homeostasis.
###end title 29
###begin p 30
SNP: Single Nucleotide Polymorphism, CI: Confidence Interval, HOMA-IR: Homeostasis Model Assessment Insulin Resistance, HOMA-B: Homeostasis Model Assessment Beta-Cell Function.
###end p 30
###begin p 31
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 266 268 266 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 334 338 334 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Zeggini1">[15]</xref>
###xml 382 384 382 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;3</sup>
###xml 565 567 565 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
###xml 582 589 582 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000768-t003">Table 3</xref>
###xml 616 620 616 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Prokopenko1">[16]</xref>
###xml 712 714 712 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;3</sup>
###xml 850 857 850 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000768-t004">Table 4</xref>
###xml 884 888 884 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Willer1">[17]</xref>
###xml 1004 1012 1004 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000768.s007">Table S4</xref>
In contrast, the risk allele rs4311394-G at ARL15, which was associated with lower adiponectin levels, was also associated with: an increased risk of CHD in a consortium of 7 CHD cohorts (Odds ratio [OR] = 1.12, [95% Confidence Interval [CI]: 1.06, 1.17], P = 8.5x10-6, n = 22,421); an increased risk of T2D in the DIAGRAM consortium [15] (OR = 1.11 [95% CI: 1.03, 1.18], P = 3.2x10-3, n = 10,128); and higher glycated hemoglobin in the European Prospective Investigation of Cancer-Norfolk (EPIC-Norfolk) cohort (0.025% per G allele [95% CI: 0.01, 0.04], P = 5.0x10-4, n = 14,168) (Table 3). In the MAGIC consortium [16], the rs4311394-G allele was associated with increased levels of fasting insulin (P = 2.3x10-3, n = 24,614), and demonstrated non-significant trends towards higher HOMA-IR (P = 0.01, n = 24,188) and HOMA-B (P = 0.02, n = 24,130) (Table 4). In the GIANT consortium [17], the same allele demonstrated a modest and non-significant association with decreased BMI (P = 0.016, n = 32,527) (Table S4), indicating that the disease and metabolic trait associations of rs4311394-G are unlikely to be mediated through an increase in BMI.
###end p 31
###begin p 32
Thus, in sum, the G allele at rs4311394 was consistently associated with an increased risk of T2D and CHD, as well as deleterious changes in the 5 metabolic traits tested.
###end p 32
###begin title 33
Expression Studies
###end title 33
###begin p 34
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 220 225 220 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 376 384 376 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000768-g003">Figure 3</xref>
###xml 611 619 611 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000768-g004">Figure 4</xref>
###xml 118 123 <span type="species:ncbi:9606">human</span>
###xml 186 191 <span type="species:ncbi:9606">human</span>
Since the function and distribution of ARL15 expression is unknown, we assessed the level of ARL15 mRNA expression in human tissues using quantitative real-time PCR across a wide set of human tissues. We identified that ARL15 was expressed most abundantly in skeletal muscle at a level 4-fold that of the mean of all other tissues, with adipose expression detectable but low (Figure 3). Using biopsied tissue from insulin-sensitive tissues (liver, skeletal muscle and adipose tissue) in healthy volunteers, immunoblots confirmed ARL15 expression in skeletal muscle, although it was detectable in all 3 tissues (Figure 4).
###end p 34
###begin title 35
Tissue distribution of ARL15 expression.
###end title 35
###begin p 36
###xml 67 72 <span type="species:ncbi:9606">human</span>
mRNA levels determined by quantitative real-time PCR in a panel of human tissues.
###end p 36
###begin title 37
###xml 71 77 <span type="species:ncbi:9606">humans</span>
Western blot showing ARL15 expression in insulin-responsive tissues in humans with alpha-tubulin as a loading control.
###end title 37
###begin p 38
###xml 91 96 <span type="species:ncbi:9606">human</span>
HEK293 = untransfected HEK293 cells; ARL15 = HEK293 cells transiently expressing wild type human ARL15. SkM = skeletal muscle; WAT = white adipose tissue.
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 121 126 121 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 261 267 261 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
By conducting a GWAS for the adipocyte-derived protein adiponectin, we have identified a novel susceptibility variant in ARL15, which is associated with lower adiponectin levels and increased risk of T2D and CHD. Our results also help clarify which variants at ADIPOQ influence adiponectin levels, thus expanding our understanding of the adiponectin pathway.
###end p 40
###begin p 41
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 26 30 26 30 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-ThierryMieg1">[20]</xref>
###xml 349 353 349 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Gillingham1">[19]</xref>
###xml 461 465 461 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Hofmann1">[21]</xref>
###xml 466 470 466 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Fuss1">[22]</xref>
###xml 471 475 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Ishiki1">[23]</xref>
###xml 476 480 476 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Hou1">[24]</xref>
###xml 520 525 520 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 764 769 764 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
ARL15 is widely expressed [20]. However its function is unknown, and there have been no phenotypes previously associated with this gene. Based on its predicted protein sequence, ARL15 is structurally similar to ADP-ribosylation factors and Ras-related GTP-binding proteins which play key roles in the regulation of intracellular vesicle trafficking [19], and which have been specifically implicated in insulin signaling and insulin-stimulated glucose transport [21],[22],[23],[24]. Our preliminary data demonstrate that ARL15 is expressed in insulin-responsive tissues, including adipose tissue. Interestingly, expression was highest in skeletal muscle, which is the main site of insulin-mediated glucose disposal, but which does not synthesize adiponectin. Thus, ARL15 is a good candidate to be involved in cellular insulin resistance and/or adiponectin trafficking and secretion. Its implication in metabolic diseases by a non-hypothesis-based genetic approach provides strong impetus for further functional studies.
###end p 41
###begin p 42
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Menzaghi1">[12]</xref>
###xml 144 148 144 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Hivert2">[13]</xref>
###xml 149 153 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Ling1">[14]</xref>
###xml 154 158 154 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Pollin1">[25]</xref>
###xml 311 317 311 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
###xml 347 356 347 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000768.s002">Figure S2</xref>
###xml 423 429 423 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
###xml 580 581 580 581 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 683 687 683 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Menzaghi1">[12]</xref>
###xml 943 947 943 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Hivert2">[13]</xref>
Our study sheds further light on the role of ADIPOQ SNPs on adiponectin levels - which has been the source of several inconsistent reports [12],[13],[14],[25] - since we have systematically tested all common HapMap CEPH (Centre d'Etude du Polymorphisme Humain) SNPs through genotyping and imputation across the ADIPOQ locus in 14,733 individuals (Figure S2). Among the SNPs previously associated with adiponectin levels at ADIPOQ, the rs1648707 SNP achieved genome-wide significance in our analysis for adiponectin. rs1648707 is in moderate linkage disequilibrium with rs266729 (r2 = 0.74), which has previously been associated with adiponectin levels, but not consistently with T2D [12]. We did not assess rare variants, and were thus unable to test the association of rs17366743 (minor allele frequency = 0.075) with adiponectin levels, which has been previously associated with T2D and with fasting glucose, but not with adiponectin levels [13].
###end p 42
###begin p 43
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
###xml 268 273 268 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 362 367 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 442 447 442 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 689 693 689 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Basu1">[26]</xref>
###xml 694 698 694 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Bluher1">[35]</xref>
###xml 878 883 878 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 1148 1153 1148 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 1234 1242 <span type="species:ncbi:9606">children</span>
###xml 1289 1297 <span type="species:ncbi:9606">Children</span>
Interestingly, ADIPOQ SNPs that showed genome-wide significant associations with adiponectin levels did not show associations with T2D or CHD. This raises the question of how ARL15 interacts with adiponectin to influence disease risk. The demonstrated relationship of ARL15 with the metabolic traits and diseases may represent adiponectin-independent effects of ARL15 - a hypothesis that could be tested by adjusting the relationship between ARL15 and CHD or T2D for adiponectin levels (which was not possible in this study, as the disease cohorts had no measured adiponectin levels). Alternatively, recent evidence suggests that adiponectin may be influenced directly by insulin exposure [26]-[35], allowing adiponectin to act as a surrogate marker for integrated total insulin exposure as a result of its stable half-life and relatively low diurnal variability. Consequently, ARL15 may be an upstream mediator of the relationship between insulin and adiponectin, and may thus impact upon T2D and CHD through an insulin-dependent pathway which involves, but is not entirely dependent upon, adiponectin. In addition, since we demonstrated that the ARL15 variant was associated with adiponectin levels across all age ranges, including children in the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort, this variant likely affects lifelong adiponectin levels, which may influence its relationship with T2D and CHD.
###end p 43
###begin p 44
###xml 135 140 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 222 228 222 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
###xml 309 314 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 394 399 394 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
In conclusion, this study expands our understanding of the genetic influences on adiponectin levels. We have implicated a novel locus, ARL15, in the regulation of adiponectin levels and clarified the role of variants near ADIPOQ on adiponectin levels. Finally, we provide further evidence that the variant at ARL15 may influence risk of T2D and CHD, thus providing impetus for further study of ARL15.
###end p 44
###begin title 45
Methods
###end title 45
###begin p 46
###xml 287 295 287 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000768-g001">Figure 1</xref>
We undertook a GWAS to detect SNPs which were associated with adiponectin, and tested the physiologic and clinical relevance of these SNPs by assessing their association with indices of glucose homeostasis and BMI in European populations, and with T2D and CHD in large clinical cohorts (Figure 1).
###end p 46
###begin title 47
Ethical Considerations
###end title 47
###begin p 48
###xml 215 227 <span type="species:ncbi:9606">participants</span>
All studies including biopsy of liver, skeletal muscle or adipose tissue from healthy volunteers for immunoblotting studies were approved by institutional ethics review committees at the relevant organizations. All participants provided informed written consent.
###end p 48
###begin title 49
Study Populations
###end title 49
###begin p 50
###xml 227 234 227 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000768-t001">Table 1</xref>
###xml 275 279 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Firmann1">[36]</xref>
###xml 289 293 289 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Andrew1">[37]</xref>
###xml 294 298 294 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Richards1">[38]</xref>
###xml 350 354 350 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Stirnadel1">[39]</xref>
###xml 775 779 775 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Richards2">[40]</xref>
###xml 356 368 <span type="species:ncbi:9606">Participants</span>
###xml 1020 1032 <span type="species:ncbi:9606">participants</span>
The first stage of the GWAS for adiponectin levels was performed in 3 population-based cohorts utilizing subjects of self-described European ancestry, which were not selected for diabetes, heart disease or any metabolic trait (Table 1). The discovery cohorts included CoLaus [36], TwinsUK [37],[38], and Genetic Etiology of Metabolic Syndrome (GEMS) [39]. Participants of the CoLaus study were individuals of European ancestry, randomly selected from 56,694 permanent residents of Lausanne, Switzerland, between the ages of 35 and 75 years. Recruitment took place between April 2003 and March 2006. TwinsUK is a population-based sample of British twins, which is representative of the general United Kingdom population, and is extensively phenotyped for aging-related traits [40]. GEMS is a case-control study of dyslipidemic individuals between the ages of 20 and 65 years. Cases and controls were matched based on gender and recruitment site. The GEMS and CoLaus studies were sponsored in part by GlaxoSmithKline. All participants were informed of this sponsorship, and consented for the use of their data and biologic samples by GlaxoSmithKline and its subsidiaries.
###end p 50
###begin p 51
###xml 69 73 69 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Hivert2">[13]</xref>
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Shock1">[41]</xref>
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Ferrucci1">[42]</xref>
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Melzer1">[43]</xref>
###xml 154 158 154 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Golding1">[44]</xref>
###xml 176 180 176 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Harding1">[45]</xref>
###xml 408 415 <span type="species:ncbi:9606">persons</span>
###xml 685 690 <span type="species:ncbi:9606">women</span>
###xml 701 709 <span type="species:ncbi:9606">children</span>
###xml 836 843 <span type="species:ncbi:9606">persons</span>
The validation cohorts included the Framingham Offspring Study (FOS) [13], Baltimore Longitudinal Study of Aging (BLSA) [41], InCHIANTI [42],[43], ALSPAC [44] and EPIC-Norfolk [45]. The FOS is a population-based sample of residents of Framingham, Massachusetts. Adiponectin was measured at exam 7 (1998-2002). BLSA is an observational study that began in 1958 to study normative aging in a cohort of healthy persons 17 years of age and older at study entry. InCHIANTI is a population-based cohort designed to study aging-related traits and disease from the Chianti geographic region (Tuscany, Italy). ALSPAC is a population-based birth cohort study consisting initially of over 13,000 women and their children recruited in the county of Avon, UK, in the early 1990s. The EPIC-Norfolk cohort is a British population-based study of white persons recruited from Norfolk, UK, between 1993 and 1997. All individuals in all replication cohorts were of self-described European descent.
###end p 51
###begin title 52
Phenotyping and Genotyping for Metabolic Traits, T2D, and CHD
###end title 52
###begin p 53
###xml 409 413 409 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Matthews1">[46]</xref>
Only the SNPs which achieved genome-wide significance for adiponectin levels in the combined analysis of data from all 8 cohorts were assessed for their relationship with adiposity-driven diseases and traits, which included: T2D, CHD, fasting glucose, glycated hemoglobin, BMI and insulin, as well as measures of insulin resistance (HOMA-IR) and beta-cell function (HOMA-B) estimated by the homeostasis model [46].
###end p 53
###begin p 54
###xml 456 460 456 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Zeggini1">[15]</xref>
###xml 461 465 461 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Rafiq1">[47]</xref>
T2D risk was estimated from the DIAGRAM consortium (a meta-analysis of 3 T2D genome-wide association scans [], which included 4,107 T2D cases and 5,187 controls). The 3 populations were the Wellcome Trust Case Control Consortium (WTCCC), the Finland-United States Investigation of NIDDM [Non-Insulin-Dependent Diabetes Mellitus] Genetics (FUSION), and the Diabetes Genetics Initiative (DGI). A full description of this meta-analysis is available elsewhere [15],[47].
###end p 54
###begin p 55
###xml 155 159 155 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Prokopenko1">[16]</xref>
###xml 790 794 790 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Prokopenko1">[16]</xref>
The association between susceptibility alleles and fasting glucose, insulin and measures of insulin resistance and beta-cell function were tested in MAGIC [16]. This consortium includes data from 36,610 individuals of European descent who were included in 4 distinct consortia: [a] The European Network for Genetic and Genomic Epidemiology (ENGAGE) project, combining data from deCODE, Northern Finland Birth Cohort 1966, Netherlands Twins Register/Netherlands Study of Depression and Anxiety and the Rotterdam study; [b] the GEMS study, which includes data from the CoLaus and TwinsUK scans; [c] DFS, which includes the DGI, FUSION and SardiNIA scans; and [d] the Framingham Heart Study. Details of all of these studies, phenotyping and genotyping protocols have been published previously [16].
###end p 55
###begin p 56
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Helgadottir1">[48]</xref>
###xml 163 167 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-McPherson1">[49]</xref>
###xml 214 218 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Samani1">[50]</xref>
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Consortium1">[51]</xref>
###xml 343 347 343 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Sandhu1">[52]</xref>
###xml 418 422 418 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Samani1">[50]</xref>
###xml 423 427 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Erdmann1">[53]</xref>
###xml 453 457 453 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Hofman1">[54]</xref>
###xml 459 467 459 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000768.s005">Table S2</xref>
###xml 657 666 657 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000768.s003">Figure S3</xref>
###xml 298 310 <span type="species:ncbi:9606">participants</span>
The association between susceptibility alleles and CHD was tested in 8 cohorts (n = 22,421). These cohorts included PennCath [48], MedStar, the Ottawa Heart Study [49], the WTCCC coronary heart disease (CAD) study [50],[51], a case-control study of CHD nested in the EPIC-Norfolk cohort comprising participants with available genome-wide data [52], German Myocardial Infarction Family Study (GerMIFS) I and GerMIFS II [50],[53], and the Rotterdam Study [54] (Table S2). The rs4311394 SNP was assessed by imputation in the GerMIFS I cohort, and did not meet quality control criteria. Thus, results for this SNP are reported for all cohorts except GerMIFS I (Figure S3). All other SNPs were assessed in all cohorts.
###end p 56
###begin p 57
###xml 58 62 58 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Willer1">[17]</xref>
###xml 63 67 63 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Loos1">[18]</xref>
###xml 237 241 237 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Willer1">[17]</xref>
Associations with BMI were tested in the GIANT consortium [17],[18], which encompasses 15 cohorts of 32,527 individuals of European descent. It has been described in detail previously, including information on genotyping and phenotyping [17].
###end p 57
###begin title 58
Genotyping
###end title 58
###begin p 59
###xml 0 8 0 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000768.s004">Table S1</xref>
###xml 329 333 329 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Sandhu1">[52]</xref>
###xml 469 473 469 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Richards2">[40]</xref>
###xml 218 223 <span type="species:ncbi:9606">Human</span>
###xml 598 603 <span type="species:ncbi:9606">Human</span>
###xml 650 655 <span type="species:ncbi:9606">Human</span>
Table S1 outlines the genotyping methods used for each cohort, individual and SNP exclusion thresholds, and imputation algorithms. For the CoLaus and GEMS studies, genotypes were obtained using the Affymetrix Genechip Human Mapping 500k array with the Bayesian Robust Linear Modeling using Mahalanobis distance (BRLMM) algorithm [52]. The TwinsUK samples were genotyped using the Illumina calling algorithm on the Illumina HumanHap300, HumanCNV370 Duo and HumanHap 550 [40]. The FOS employed the Affymetrix 500k and MIPS 50k genotyping arrays. Both the BLSA and InCHIANTI cohorts used the Illumina Human Hap 550 genotyping arrays, while the Illumina Human Hap300 array was used in the ALSPAC cohort. Targeted genotyping was performed in the EPIC-Norfolk cohort using TaqMan SNP genotyping assay (Applied Biosystems, Warrington, UK) according to the manufacturer's protocol. Genotype frequencies were in Hardy Weinberg Equilibrium (HWE) (P>0.50), call rates were >94% and concordances were >98% for the TaqMan assay.
###end p 59
###begin title 60
Adiponectin Measurement
###end title 60
###begin p 61
###xml 393 397 381 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Richards1">[38]</xref>
###xml 553 557 541 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Hivert2">[13]</xref>
The TwinsUK and EPIC-Norfolk cohorts measured adiponectin levels with an in-house 2-site enzyme-linked immunosorbent assay (ELISA) using antibodies and standards from R&D Systems Europe (Abingdon, Oxford, UK) in plasma. The day-to-day coefficients of variation (CV) for adiponectin were 5.4%, 5.2%, and 5.8% at a concentration of 3.6 microg/ml, 9.2 microg/ml, and 15.5 microg/ml, respectively [38]. The FOS, CoLaus and GEMS measured adiponectin using the ELISA assay (R&D Systems, Minneapolis, Minnesota, United States of America; Intra-assay CV: 5.8%) [13]. Importantly, while CoLaus and GEMs measured adiponectin in plasma, the FOS measured adiponectin in serum. The ALSPAC cohort measured adiponectin using a commercially available ELISA kit (R&D systems, Oxon, UK) previously validated against the corresponding radio-immunoassay (RIA). The inter-assay CV for this adiponectin assay was <7.5%. The InCHIANTI and BLSA studies measured adiponectin levels using the adiponectin RIA assay of Linco Research (St. Charles, Missouri, USA). The detectable ranges for the RIA assay used in InCHIANTI and BLSA are 0.78 microg/ml-200 microg/ml.
###end p 61
###begin title 62
Expression Experiments
###end title 62
###begin p 63
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 596 601 592 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 663 668 659 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
###xml 712 716 708 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPIA</italic>
###xml 734 738 730 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPIA</italic>
###xml 748 769 744 765 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ACGGCGAGCCCTTGG-3&#8242;</named-content>
###xml 779 807 775 803 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- TTTCTGCTGTCTTTGGGACCT-3&#8242;</named-content>
###xml 832 875 828 871 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-[FAM] CGCGTCTCCTTTGAGCTGTTTGCA[TAMRA]-3&#8242;</named-content>
###xml 1834 1838 1826 1830 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">ATCC</named-content>
###xml 33 38 <span type="species:ncbi:9606">human</span>
###xml 119 124 <span type="species:ncbi:9606">human</span>
###xml 1503 1509 <span type="species:ncbi:9986">rabbit</span>
###xml 1515 1520 <span type="species:ncbi:9606">human</span>
###xml 1636 1641 <span type="species:ncbi:9606">human</span>
Relative levels of ARL15 mRNA in human tissues were assessed by quantitative real-time PCR of a commercially available human tissue panel of RNA (AMS Biotechnology, Abingdon, UK). 500 ng of RNA were reverse-transcribed using 125 ng of random hexamers and 500 microM deoxynucleotide triphosphates (dNTPs) (both from Promega, Madison, Wisconsin, USA) and 500 ng of Superscript III reverse transcriptase (Invitrogen). Gene expression was quantified on an ABI7900 Real-Time PCR system (Applied Biosystems, Foster City, California, USA) in TaqMan Mastermix (Applied Biosystems). Primers and probe for ARL15 were supplied by Applied Biosystems (ABI Hs00219491_m1), and ARL15 expression was normalized to expression of PPIA (Cyclophilin A). PPIA primers (5'-ACGGCGAGCCCTTGG-3' (sense), 5'- TTTCTGCTGTCTTTGGGACCT-3' (antisense)) and probe (5'-[FAM] CGCGTCTCCTTTGAGCTGTTTGCA[TAMRA]-3') were synthesized by Sigma-Aldrich. Skeletal muscle biopsies were a gift from Dr Anna Krook, from the Karolinska Institute. Frozen skeletal muscle, liver and white adipose tissue samples were homogenized in lysis buffer (50 mM Tris-HCl, pH8.0, 150 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, and Complete Protease Inhibitor Cocktail [Roche]), and cell debris removed by centrifugation. Cleared supernatants were boiled in sodium dodecyl sulphate (SDS) sample buffer and run on an SDS polyacrylamide gel before transfer to a polyvinylidene difluoride (PVDF) membrane (Amersham) and subsequent immunoblotting with either purified rabbit anti-human ARL15 antibody (Proteintech Group) or anti-alpha-tubulin antibody (sc-8035; Santa Cruz Biotechnology). Full-length human wild type ARL15 cDNA was purchased from Open Biosystems and subcloned into pCDNA 3.1 (Invitrogen) using the XhoI and HindIII restriction sites. HEK293 cells (American Type Culture Collection [ATCC]) were transiently transfected using the CalPhos Mammalian Tranfection Kit (Clontech) according to the manufacturer's instructions.
###end p 63
###begin title 64
Statistical Methods
###end title 64
###begin p 65
###xml 238 241 238 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Lindsay1">[4]</xref>
###xml 242 245 242 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Weyer1">[5]</xref>
###xml 689 691 689 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
In all cohorts, the adiponectin concentrations were natural logarithm transformed to create a normally distributed phenotype. Adiponectin levels were subsequently adjusted for age, sex and BMI - important correlates of adiponectin levels [4],[5]. All results reported for association of genetic variants with adiponectin levels are adjusted for age, sex and BMI. All statistical tests assumed an additive effect of the effect allele. In the TwinsUK cohort, we found that there was little difference when comparing results both adjusted, and unadjusted, for BMI (the Spearman coefficients for the beta coefficients was 0.94 and 1.0 for P-values [P-values for both Spearman coefficients<1x10-5]).
###end p 65
###begin p 66
###xml 29 33 29 33 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Consortium1">[51]</xref>
###xml 152 156 152 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Abecasis1">[55]</xref>
###xml 488 492 488 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Folks1">[56]</xref>
The SNPTEST software program [51] was used to perform genome-wide association testing in the GEMS and CoLaus cohorts, while the Merlin software package [55] was used to perform association testing in the TwinsUK cohort. The meta-analysis of the discovery phase cohorts (CoLaus, TwinsUK and GEMS) was performed using Liptak-Stouffer's method for combination of independent tests, where P-values are converted to Z-scores by a standard normal curve and weighted by each study's sample size [56].
###end p 66
###begin p 67
###xml 50 52 48 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
###xml 239 245 237 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
###xml 299 301 295 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
All SNPs that achieved a combined P-value of </=10-4 in the meta-analysis (n = 250) were tested for their association in the additional cohorts (InCHIANTI, BLSA, ALSPAC and the Framingham Offspring Cohort). Two SNPs that were not near the ADIPOQ locus, and which demonstrated associations of </=5x10-7 with adiponectin levels in the combined analysis, were further verified in an additional replication cohort (EPIC-Norfolk), where association with adiponectin was tested using a generalized linear model. For the quantitative trait analyses, individuals with known T2D were excluded. For the T2D case-control analyses, each SNP was tested for association using a logistic regression analysis, adjusted for age, sex and BMI. All analyses for the EPIC-Norfolk cohort were performed with SAS 9.1 (SAS Institute Inc., Cary, North Carolina, USA). To perform a meta-analysis of all replication and discovery cohorts, we employed inverse-variance techniques in the STATA software package (College Station, Texas, USA).
###end p 67
###begin p 68
###xml 60 62 58 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 275 279 269 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Frazer1">[57]</xref>
###xml 724 730 718 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
###xml 844 850 838 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
###xml 857 861 851 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Nyholt1">[58]</xref>
###xml 953 958 947 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
We declared statistical significance in the GWAS as P</=5x10-8, where this threshold is based on a Bonferroni correction of alpha = 0.05 divided by one million, the estimated number of independent common tests among common SNPs in the CEU population of the HapMap II project [57]. Using this threshold, 5 SNPs achieved genome-wide significance for their relationship with circulating adiponectin levels in the combined analysis of all adiponectin cohorts. These were subsequently tested for their association with glycated hemoglobin, indices of insulin resistance, beta-cell function and risk of T2D and CHD. The number of independent statistical tests represented by these 5 SNPs, accounting for linkage disequilibrium at ADIPOQ, was assessed by spectral decomposition of matrices of pairwise linkage disequilibrium between the 4 SNPs at the ADIPOQ locus [58]. In total, 3.59 independent statistical tests were performed at this locus, and one at the ARL15 locus. Thus, statistical significance in the follow-up studies was declared at P</=0.011 (based on a Bonferroni correction of alpha = 0.05 divided by 4.59, the number of statistically independent SNPs tested in the follow-up analyses).
###end p 68
###begin p 69
###xml 295 299 295 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000768-Higgins1">[59]</xref>
###xml 175 183 <span type="species:ncbi:9606">children</span>
Since 2 cohorts measured adiponectin concentrations using an RIA method (BLSA and InCHIANTI) whilst all others used an ELISA method, and since one study, ALSPAC, was based on children, rather than adults, we tested for evidence of heterogeneity in the combined analysis using the Q-test P-value [59].
###end p 69
###begin title 70
Supporting Information
###end title 70
###begin p 71
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
###xml 421 428 421 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000768-t002">Table 2</xref>
Association between SNPs near ADIPOQ and Adiponectin levels. (A) -log (P value) measures for association between SNPs and chromosomal position. (B) Entrez Genes. (C) Linkage disequilibrium in GOLD heat map Haploview 4.0 color scheme, CEPH population. The x axis represents genomic position in Mb (A) and in kb (B,C). All P values are derived from the discovery meta-analysis, except for the genome-wide significant SNPs (Table 2), which are derived from the combined P values from all cohorts (displayed in red).
###end p 71
###begin p 72
(1.13 MB TIF)
###end p 72
###begin p 73
Click here for additional data file.
###end p 73
###begin p 74
###xml 115 121 115 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADIPOQ</italic>
Relationship of genome-wide significant SNPs from the current study with selected previously published SNPs at the ADIPOQ locus.
###end p 74
###begin p 75
(1.54 MB TIF)
###end p 75
###begin p 76
Click here for additional data file.
###end p 76
###begin p 77
Forest Plot of Association of rs4311394 with Risk of CHD (total n = 22,421).
###end p 77
###begin p 78
(0.28 MB TIF)
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin p 80
Genotyping information for the adiponectin discovery and replication cohorts.
###end p 80
###begin p 81
(0.04 MB DOC)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin p 83
Cohort information, case and control definitions for coronary heart disease cohorts. (A) Cohort information for coronary heart disease cohorts and (B) Case and control definitions for coronary heart disease cohorts.
###end p 83
###begin p 84
(0.05 MB DOC)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin p 86
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARL15</italic>
Quality control parameters for rs4311394 at ARL15 from each cohort involved in the adiponectin GWAS.
###end p 86
###begin p 87
(0.03 MB DOC)
###end p 87
###begin p 88
Click here for additional data file.
###end p 88
###begin p 89
Relationship of genome-wide significant SNPs with body mass index (BMI) in the GIANT consortium.
###end p 89
###begin p 90
(0.03 MB DOC)
###end p 90
###begin p 91
Click here for additional data file.
###end p 91
###begin p 92
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GIANT</italic>
Genetic Investigation of Anthropometric Traits (GIANT) Consortium.
###end p 92
###begin p 93
(0.05 MB DOC)
###end p 93
###begin p 94
Click here for additional data file.
###end p 94
###begin p 95
###xml 501 508 501 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000768.s008">Text S1</xref>
###xml 19 31 <span type="species:ncbi:9606">participants</span>
We thank all study participants, volunteers, and study personnel that made this consortium possible. DELFIA Adiponectin Assays were performed by the NIHR Cambridge Biomedical Research Centre, Core Biochemical Assay Laboratory. We would like to thank Renee Atallah for her help with the manuscript. We acknowledge the contributions of the GIANT consortium, which provided summary statistics for the relationship between the genome-wide significant SNPs and BMI. Members of the consortium are listed in Text S1.
###end p 95
###begin title 96
References
###end title 96
###begin article-title 97
Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance.
###end article-title 97
###begin article-title 98
Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity.
###end article-title 98
###begin article-title 99
Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters.
###end article-title 99
###begin article-title 100
Adiponectin and development of type 2 diabetes in the Pima Indian population.
###end article-title 100
###begin article-title 101
Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.
###end article-title 101
###begin article-title 102
Adiponectin and protection against type 2 diabetes mellitus.
###end article-title 102
###begin article-title 103
###xml 63 66 <span type="species:ncbi:9606">Men</span>
Plasma Adiponectin Levels and Risk of Myocardial Infarction in Men.
###end article-title 103
###begin article-title 104
###xml 77 82 <span type="species:ncbi:9606">human</span>
Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance.
###end article-title 104
###begin article-title 105
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 60 65 <span type="species:ncbi:9606">human</span>
The metabolism of isoforms of human adiponectin: studies in human subjects and in experimental animals.
###end article-title 105
###begin article-title 106
The genetic basis of plasma variation in adiponectin, a global endophenotype for obesity and the metabolic syndrome.
###end article-title 106
###begin article-title 107
Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians.
###end article-title 107
###begin article-title 108
Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease.
###end article-title 108
###begin article-title 109
Common variants in the adiponectin gene (ADIPOQ) associated with plasma adiponectin levels, type 2 diabetes, and diabetes-related quantitative traits: the Framingham Offspring Study.
###end article-title 109
###begin article-title 110
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes.
###end article-title 110
###begin article-title 111
Variants in MTNR1B influence fasting glucose levels.
###end article-title 111
###begin article-title 112
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation.
###end article-title 112
###begin article-title 113
Common variants near MC4R are associated with fat mass, weight and risk of obesity.
###end article-title 113
###begin article-title 114
The small G proteins of the Arf family and their regulators.
###end article-title 114
###begin article-title 115
AceView: a comprehensive cDNA-supported gene and transcripts annotation.
###end article-title 115
###begin article-title 116
The Arl4 family of small G proteins can recruit the cytohesin Arf6 exchange factors to the plasma membrane.
###end article-title 116
###begin article-title 117
###xml 61 71 <span type="species:ncbi:7227">Drosophila</span>
The cytohesin Steppke is essential for insulin signalling in Drosophila.
###end article-title 117
###begin article-title 118
Minireview: recent developments in the regulation of glucose transporter-4 traffic: new signals, locations, and partners.
###end article-title 118
###begin article-title 119
Ins (endocytosis) and outs (exocytosis) of GLUT4 trafficking.
###end article-title 119
###begin article-title 120
Linkage of plasma adiponectin levels to 3q27 explained by association with variation in the APM1 gene.
###end article-title 120
###begin article-title 121
Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects.
###end article-title 121
###begin article-title 122
###xml 106 112 <span type="species:ncbi:9606">humans</span>
Hyperglycemia prevents the suppressive effect of hyperinsulinemia on plasma adiponectin levels in healthy humans.
###end article-title 122
###begin article-title 123
###xml 73 79 <span type="species:ncbi:9606">humans</span>
Insulin and endothelin in the acute regulation of adiponectin in vivo in humans.
###end article-title 123
###begin article-title 124
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes.
###end article-title 124
###begin article-title 125
Elevated circulating adiponectin in type 1 diabetes is associated with long diabetes duration.
###end article-title 125
###begin article-title 126
###xml 40 48 <span type="species:ncbi:9606">children</span>
Elevated serum levels of adiponectin in children, adolescents and young adults with type 1 diabetes and the impact of age, gender, body mass index and metabolic control: a longitudinal study.
###end article-title 126
###begin article-title 127
Elevated levels of high-molecular-weight adiponectin in type 1 diabetes.
###end article-title 127
###begin article-title 128
###xml 31 37 <span type="species:ncbi:9606">humans</span>
Elevated plasma adiponectin in humans with genetically defective insulin receptors.
###end article-title 128
###begin article-title 129
Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies.
###end article-title 129
###begin article-title 130
Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance.
###end article-title 130
###begin article-title 131
The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome.
###end article-title 131
###begin article-title 132
###xml 103 108 <span type="species:ncbi:9606">women</span>
Are twins and singletons comparable? A study of disease-related and lifestyle characteristics in adult women.
###end article-title 132
###begin article-title 133
###xml 46 51 <span type="species:ncbi:9606">women</span>
Serum adiponectin and bone mineral density in women.
###end article-title 133
###begin article-title 134
Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: the GEMS Study.
###end article-title 134
###begin article-title 135
Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study.
###end article-title 135
###begin article-title 136
###xml 7 12 <span type="species:ncbi:9606">Human</span>
Normal Human Aging: The Baltimore Longitudinal Study of Aging.
###end article-title 136
###begin article-title 137
Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study.
###end article-title 137
###begin article-title 138
A genome-wide association study identifies protein quantitative trait loci (pQTLs).
###end article-title 138
###begin article-title 139
###xml 50 58 <span type="species:ncbi:9606">Children</span>
ALSPAC-the Avon Longitudinal Study of Parents and Children. I. Study methodology.
###end article-title 139
###begin article-title 140
Fat consumption and HbA(1c) levels: the EPIC-Norfolk study.
###end article-title 140
###begin article-title 141
###xml 131 134 <span type="species:ncbi:9606">Man</span>
Homeostasis Model Assessment - Insulin Resistance and Beta-Cell Function from Fasting Plasma-Glucose and Insulin Concentrations in Man.
###end article-title 141
###begin article-title 142
Gene variants influencing measures of inflammation or predisposing to autoimmune and inflammatory diseases are not associated with the risk of type 2 diabetes.
###end article-title 142
###begin article-title 143
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction.
###end article-title 143
###begin article-title 144
A common allele on chromosome 9 associated with coronary heart disease.
###end article-title 144
###begin article-title 145
Genomewide association analysis of coronary artery disease.
###end article-title 145
###begin article-title 146
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.
###end article-title 146
###begin article-title 147
LDL-cholesterol concentrations: a genome-wide association study.
###end article-title 147
###begin article-title 148
New susceptibility locus for coronary artery disease on chromosome 3q22.3.
###end article-title 148
###begin article-title 149
The Rotterdam Study: objectives and design update.
###end article-title 149
###begin article-title 150
Merlin-rapid analysis of dense genetic maps using sparse gene flow trees.
###end article-title 150
###begin article-title 151
Combination of independent tests;
###end article-title 151
###begin article-title 152
###xml 20 25 <span type="species:ncbi:9606">human</span>
A second generation human haplotype map of over 3.1 million SNPs.
###end article-title 152
###begin article-title 153
A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other.
###end article-title 153
###begin article-title 154
Measuring inconsistency in meta-analyses.
###end article-title 154
###begin p 155
The authors have declared that no competing interests exist.
###end p 155
###begin p 156
###xml 764 772 <span type="species:ncbi:9606">Children</span>
This work was supported, in part, by grants from the Wellcome Trust (to RKS: Intermediate Clinical Fellowship 080952/Z/06/Z; to SOR: Programme Grant 078986/Z/06/Z), the United Kingdom Medical Research Council Centre for Obesity and Related Metabolic Diseases. The Canadian Institutes of Health Research (CIHR) provided support to this project to JBR, MFH, and TP). DELFIA Adiponectin Assays were performed by the NIHR Cambridge Biomedical Research Centre, Core Biochemical Assay Laboratory. Recruitment of the PennCATH cohort was supported by the Cardiovascular Institute of the University of Pennsylvania. Recruitment of the MedStar cohort was supported by a research grant from GlaxoSmithKline. Genotyping was performed at the Center for Applied Genomics at the Children's Hospital of Philadelphia and supported by GlaxoSmithKline through an Alternate Drug Discovery Initiative research alliance award (to MPR and DJR) with the University of Pennsylvania School of Medicine. The German Study was supported by the Deutsche Forschungsgemeinschaft and the German Federal Ministry of Education and Research (BMBF) in the context of the German National Genome Research Network (NGFN-2 and NGFN-plus) and the EU-funded integrated project Cardiogenics (LSHM-CT-2006-037593). The KORA research platform (KORA, Cooperative Research in the Region of Augsburg) was initiated and financed by the GSF National Research Centre for Environment and Health, which is funded by the German Federal Ministry of Education and Research and the State of Bavaria. The EPIC Norfolk Study is funded by Cancer Research United Kingdom and the Medical Research Council. The WTCCC Study was funded by the Wellcome Trust. Recruitment of cases for the WTCCC Study was carried out by the British Heart Foundation (BHF) Family Heart Study Research Group and supported by the BHF and the UK Medical Research Council. NJS holds a Chair funded by the BHF. The UK Medical Research Council, the Wellcome Trust, and the University of Bristol provide core support for ALSPAC; and this ALSPAC study was specifically funded by the British Heart Foundation # MRC PG/07/002. The gene expression work was supported by Genome Quebec, Genome Canada, and the CIHR. TP holds a Canada Research Chair, and Drs. O. Nilsson, Ljunggren, and H. Mallmin (Uppsala University, Sweden) are acknowledged for collection of the osteoblasts. The Framingham Heart Study component of this work was supported by the National Heart, Lung, and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195), its contract with Affymetrix for genotyping services (Contract No.N02-HL-6-4278), and the resources of the Framingham Heart Study SNP Health Association Resource (SHARe) project, the National Institutes of Health, National Center for Research Resources, General Clinical Research Centers Program (Grant Number M01-RR-01066), an American Diabetes Association Career Development Award (JBM), a research grant from sanofi-aventis (JBM), the Boston University Linux Cluster for Genetic Analysis (LinGA) funded by the NIH NCRR Shared Instrumentation grant (1S10RR163736-01A1), and the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center, by the National Heart, Lung, and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195), National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) R01 DK078616 to JBM, JD, and JCF, NIDDK K24 DK080140 to JBM, NIDDK Research Career Award K23 DK65978, a Massachusetts General Hospital Physician Scientist Development Award and a Doris Duke Charitable Foundation Clinical Scientist Development Award to JCF, and the Boston University Linux Cluster for Genetic Analysis (LinGA) funded by the NIH NCRR Shared Instrumentation grant (1S10RR163736-01A1). MFH was supported by the Centre de Recherche Medicale de l'Universite de Sherbrooke (CRMUS) and the CIHR. TwinsUK: The study was funded by the Wellcome Trust, European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F2-2008-201865-GEFOS and (FP7/2007-2013), ENGAGE project grant agreement HEALTH-F4-2007-201413, and the FP-5 GenomEUtwin Project (QLG2-CT-2002-01254). The study also receives support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. TDS is an NIHR senior Investigator. The project also received support from a Biotechnology and Biological Sciences Research Council (BBSRC) project grant (G20234). The authors acknowledge the funding and support of the National Eye Institute via an NIH/CIDR genotyping project (PI: Terri Young). We thank the staff from the Genotyping Facilities at the Wellcome Trust Sanger Institute for sample preparation, quality control, and genotyping led by Leena Peltonen and Panos Deloukas; Le Centre National de Genotypage, France, led by Mark Lathrop, for genotyping; Duke University, North Carolina, USA, led by David Goldstein, for genotyping; and the Finnish Institute of Molecular Medicine, Finnish Genome Center, University of Helsinki, led by Aarno Palotie. Genotyping was also performed by CIDR as part of an NEI/NIH project grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 156

